Late-Breaking Research: Clinical Research 1

• LB001 Dynamic circuit remodeling during glioblastoma progression: Depth-resolved electrophysiology and cortical imaging define network biomarkers Murat Yildirim, Tenesha Connor, Maryam Faisal, Omer Dinc, Kemal Ozdemirli, Frederick Bell, Berfin Dinc, Miguel Maldonado, Daniel Silver, Anthony Sloan, Justin Lathia
• LB002 · PDF Nutrigenomic stratification defines an HMGCS2-low, high-risk EO-CRC subset with a targetable stress-response vulnerability Chia-Wei Cheng, Joel T. Gabre, Han-Mo Chiu, Lindsay LaFave, Iok In Christine Chio, Timothy C. Wang
• LB003 · PDF Integrated computational design and cDNA display selection enable cyclic peptide radiopharmaceutical ligand discovery Josephine L. Fieger, Braxton V. Bell
• LB005 · PDF DLL3 expression on circulating tumor cells predicts response to bispecific antibody tarlatamab Avanish Mishra, Catherine Meador, Kruthika Kikkeri, Quinn Cunneely, Maoxuan Lin, Thomas Carmona-LaSalle, Shih-Bo Huang, Remy Bell, Victor Putaturo, Weikun Xia, Joyce Liang, Jacy Fang, Sarah San Vicente, Caroline Zielinski, Subba Digumarthy, Yin Hung, Beow Yeap, Jon Edd, Michael Lawrence, Moshe Sade-Feldman, Debattama Sen, Mehmet Toner, Shyamala Maheswaran, Justin Gainor, Daniel Haber
• LB006 · PDF Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177 Lu-PSMA-617 therapy Arthur P. McDeed, Robert Patton, Roman Gulati, Lukas Owens, Patricia Galipeau, Pooja Chandra, Aditya Pawar, Weston Hanson, Ruth Dumpit, Amir Iravini, Alireza Ghodsi, Delphine Chen, Michael T. Schweizer, Ruben Raychaudhuri, Michael Haffner, Gavin Ha, Peter S. Nelson
• LB008 · PDF Tumor CTR1 and serum copper dynamics reveal a coordinated copper axis linked to high-grade triple-negative breast cancer biology Vinit C. Shanbhag, Nikita Gudekar, Muhammad Yasir, Kristyn Conrad, Samuel Anakpeba-Dinguyella, Parshad Sutar, Praveen Rao, Michael Petris, Linda Vahdata, Christos Papageorgiou
• LB009 · PDF Mapping the spatiotemporal dynamics of CD44v9 reveals a senescent cell therapy-resistant niche in pancreatic cancer Ugonna Ezuma-Igwe, Xi Sun, Abigail G. Branch, Sangmin Kim, Rohan Kanakamedala, Payton Stevens, Jiang Wang, Syed A. Ahmad, Davendra Sohal, Petros G. Nikolinakos, James Griffin, Yana Zavros
• LB010 · PDF First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2 Yelena Y. Janjigian, Hanneke van Laarhoven, Sun Young Rha, Vadim Kozlov, Keun-Wook Lee, Do-Youn Oh, Adriano Gravina, Min-Hee Ryu, Liane Rapatoni, Luís Antunes, Filippo Pietrantonio, Hirokazu Shoji, Ralf-Dieter Hofheinz, Maxime Chénard-Poirier, Li-Tzong Chen, Aleksandr Vasiliev, Svetlana Kutukova, Arthur W. Lambert, Kun Yu, Megan Scott, Roy Rabbie, Jeeyun Lee
• LB011 · PDF Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Miaozhen Qiu, Kai Wang, Jingwen Shi, Yang Shi, Mingyu Lai, Jing Yang, Do-Youn Oh, Yuxian Bai, Ruiqi Huang, David Shames, Rui-Hua Xu
• LB012 · PDF EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2 Markus Eckstein, Qin Tjokrosurjo, Stephen J. Blakemore, Daniel A. Peterson, Kevin Magalhaes, Johannes Brägelmann, Niklas Klümper
• LB013 · PDF Lorlatinib in advanced ALK-positive non-small cell lung cancer: Efficacy, safety and exploration of predictive biomarkers for therapeutic response Fang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang
• LB014 · PDF HSPBP1 9 bp insertion mutation concurrent with pro-apoptosis and NF-κB genomic integrity predicts response to bortezomib-mediated proteasome inhibition in recurrent glioblastoma treated in NCT03643549 trial Marianne H. Hannisdal, Mohummad A. Rahman, Nello Blaser, Leif Oltedal, Judit Haaz, Arvid Lundervold, Petter Brandal, Tora S. Solheim, Dorota Goplen, Martha Chekenya
• LB015 · PDF Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trials. Alvaro Köhn-Luque, Leonard Schmiester, Vessela Kristensen
• LB016 · PDF Sensitive detection of MYCN amplified neuroblastoma in blood samples with structural variants using standard whole genome sequencing Pandurang Kolekar, Rebecca S. Kaufman, Hanxia Li, Yanling Liu, Yuan Feng, Bo Wang, Xi Wang, Li Fan, Lu Wang, Jinghui Zhang, John M. Maris, Sharon J. Diskin, Xiaotu Ma
• LB017 · PDF Cluster of differentiation 44 variant isoform 9 defines cancer stem cell reservoirs in pancreatic intraepithelial neoplastic spatial niches Xi Sun, Ugonna Ezuma-Igwe, Abigail G. Branch, Jiang Wang, Juanita L. Merchant, Syed A. Ahmad, Davendra Sohal, Petros G. Nikolinankos, James Griffin, Yana Zavros

在完整检索应用中浏览本分会场 →